SCHEMBL30748855

SCHEMBL30748855

O=C1N(c2ccc(N3CCOCC3)cc2)c2nc(CO)nc(NC3CC3)c2C12CCCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 8/20 0.39
ADORA3 P0DMS8 6/20 0.39
MEN1 O00255 1/20 0.38
AURKA O14965 1/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
TTK P33981 1/20 0.38
JAK3 P52333 1/20 0.38
KMT2A Q03164 1/20 0.38
AURKB Q96GD4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
AURKC Q9UQB9 1/20 0.38
EML4 Q9HC35 1/20 0.38
ALK Q9UM73 1/20 0.38
MAPT P10636 1/20 0.37
ALOX5 P09917 2/20 0.36
GAA P10253 1/20 0.36
FLT3 P36888 1/20 0.36
TYRO3 Q06418 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748971 0.89 MAOB (0.40) SYKJAK3EML4ALKFLT3
SCHEMBL31691331 0.85 SYK (0.36) SYKADORA3MEN1AURKAJAK2
SCHEMBL30748928 0.84 MAPT (0.34) SYKMEN1KMT2AMAPT
SCHEMBL30749050 0.82 AR (0.32) ADORA3MEN1KMT2A
SCHEMBL30749110 0.82 MAPT (0.33) SYKMEN1KMT2AMAPT
SCHEMBL30749074 0.81 L3MBTL1 (0.35) SYKMAPTGAA
SCHEMBL31691422 0.81 CHRM3 (0.37) SYKMEN1KMT2AMAPTFLT3
SCHEMBL31691360 0.80 TTK (0.33) SYKADORA3MEN1AURKAJAK2
SCHEMBL30749139 0.77 MAOB (0.41) SYKJAK3EML4ALKGAA
SCHEMBL30748933 0.76 SYK (0.40) SYKJAK2JAK1TTKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT SYK 2316/4885ADORA3 2867/4885MEN1 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.